Loading clinical trials...
Loading clinical trials...
Assessment of efficacy and safety of implantable spacers when used to reduce the radiation dose delivered to the organs at risk in prostate cancer patients undergoing radiotherapy.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
BioProtect
NCT07580196 · Prostate Cancer
NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer
NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Institute of Maria Skłodowska, Curie (MCMCC)
Warsaw
Cuf Porto institution
Porto
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions